Valeant Pharmaceuticals International Inc. appointed William Humphries executive vice president of dermatology, effective Jan. 2, 2017.

Humphries will join the company's executive committee and report directly to Chairman and CEO Joseph Papa. Humphries recently served as CEO of the North America business of Merz GmbH & Co. KGaA.

Anne Whitaker, Rob Rosiello and Ari Kellen are also set to leave Valeant's executive team. Both Whitaker and Kellen served as executive vice president and company group chairman, while Rosiello served as the company's CFO from July 2015 through August 2016.

Whitaker will leave Jan. 13, 2017. Rosiello and Kellen, who will step down from their positions Dec. 31, will remain with the company as consultants.